
AI is increasingly being used in drug discovery to reduce the time and cost of developing new pharmaceuticals. By using AI for predictive design, companies can virtually create and test drug candidates, potentially improving success rates. However, the effectiveness of AI depends on access to comprehensive data, including often-overlooked negative results. The future of drug discovery may involve fully autonomous labs, which could further enhance efficiency and success in bringing new drugs to market.
Read originalEarlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
WIRED AI · April 29, 2026 · Background
Sifted · April 30, 2026 · Background
TechCrunch AI · May 18, 2026 · Related
MIT News AI · May 20, 2026 · Related
OpenAI · June 17, 2026 · Related
AI News · July 3, 2026 · Background
The Verge AI · July 3, 2026 · Related
WIRED AI · July 12, 2026 · Related
Sifted · August 5, 2026 · Related
The Rundown AI · August 7, 2026 · Related
MIT Technology Review AI · August 10, 2026 · Related
TechCrunch AI · August 19, 2026 · Related
The Rundown AI · August 20, 2026 · Related
AI Revolutionizes Biologic Drug Discovery
2 developments
© Cole MedinAnthropic’s latest research exposes a quiet but dangerous flaw in agentic workflows: experts follow AI recommendations 86% of the time, often adopting the agent's reasoning as their own. This isn't just about accuracy; it's about cognitive capture, where human oversight dissolves into passive compliance. The study shows that even when users believe they are steering, the agent’s framing dictates the outcome. Practitioners must now actively counter this bias by forcing agents to justify deviations or prototype alternatives before committing to a path. This shift demands a new discipline in how we interact with coding assistants. We can no longer assume our intent drives the result; the model's suggestion often becomes the default truth. The real work is ensuring we remain the architects, not just the approvers.
© WIRED AICisco Talos has uncovered a new infostealer strain that actively uses commercial LLMs to profile victims and prioritize high-value targets. Dubbed Volta-Autodoxer, the malware collects credentials and browsing data, then feeds this into models like Claude Opus 4.6 via OpenRouter to generate structured intelligence dossiers. This marks a shift from passive data theft to active, AI-driven triage, allowing attackers to bypass guardrails with fallback models like Kimi K2 or Gemini. The capability foreshadows a future where lower-sophistication criminals can execute sophisticated, targeted attacks at scale.
© Matt WolfeOpenAI researchers published findings disproving the Exponential Time Hypothesis, a major result in computational complexity theory.